Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2015

01-08-2015 | PRECLINICAL STUDIES

Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells

Authors: Victor Kuete, Arno R. Nanfack Donfack, Armelle T. Mbaveng, Maen Zeino, Pierre Tane, Thomas Efferth

Published in: Investigational New Drugs | Issue 4/2015

Login to get access

Summary

Introduction Multidrug resistance in cancer represents a major problem in chemotherapy. The present study was designed to assess the cytotoxicity of anthraquinones from Pentas schimperi, namely damnacanthal (1), damnacanthol (2), 3-hydroxy-2-hydroxymethyl anthraquinone (3) and schimperiquinone B (4) against nine drug-sensitive and multidrug resistant (MDR) cancer cell lines. Methods The resazurin reduction assay was used to evaluate the cytotoxicity of the above compounds, whilst caspase-Glo assay was used to detect the activation of caspases enzymes by compounds 1 and 2. Cell cycle, mitochondrial membrane potential (MMP) and levels of reactive oxygen species were all analyzed via flow cytometry. Results Anthraquinones 1 and 2 displayed cytotoxic effects with IC50 values below 81 μM on all the nine tested cancer cell lines whilst 3 and 4 displayed selective activities. The recorded IC50 values for compounds 1 and 2 ranged from 3.12 μM and 12.18 μM (towards leukemia CCRF-CEM cells) and from 30.32 μM and 80.11 μM (towards gliobastoma U87MG.ΔEGFR cells) respectively, and from 0.20 μM (against CCRF-CEM cells) to 195.12 μM (against CEM/ADR5000 cells) for doxorubicin. Compounds 1 and 2 induced apoptosis in CCRF-CEM leukemia cells, mediated by the disruption of the MMP and increase in ROS production. Conclusions Anthraquinones from Pentas schimperi and mostly 1 and 2 are potential cytotoxic natural products that deserve more investigations to develop novel antineoplastic drugs against multifactorial drug resistant cancers.
Literature
1.
Shen B, Li D, Dong P, Gao S (2011) Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma. Ann Otol Rhinol Laryngol 120:820–827PubMedCrossRef
2.
Biedler JL, Spengler BA (1994) Reverse transformation of multidrug-resistant cells. Cancer Metastasis Rev 13:191–207PubMedCrossRef
3.
Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64:382–394PubMedCrossRef
4.
Efferth T, Sauerbrey A, Halatsch ME, Ross DD, Gebhart E (2003) Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch Pharmacol 367:56–67PubMedCrossRef
5.
el-Deiry WS (1997) Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 9:79–87PubMedCrossRef
6.
Kuete V (2013) Medicinal Plant Research in Africa. In: Kuete V (ed) Pharmacology and Chemistry, 1st edn. Elsevier, Oxford
7.
Dave H, Ledwani L (2012) A review on anthraquinones isolated from Cassia species and their applications. Indian J Nat Prod Res 3:291–319
8.
Eyong KO, Kuete V, Efferth T (2013) 10 - Quinones and Benzophenones from the Medicinal Plants of Africa. In: Kuete V (ed) Medicinal Plant Research in Africa. Elsevier, Oxford, pp 351–391CrossRef
9.
Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793–6799PubMed
10.
Gillet J, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64:8987–8993PubMedCrossRef
11.
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665–15670PubMedCentralPubMedCrossRef
12.
Kuete V, Tchakam PD, Wiench B, Ngameni B, Wabo HK, Tala MF, Moungang ML, Ngadjui BT, Murayama T, Efferth T (2013) Cytotoxicity and modes of action of four naturally occuring benzophenones: 2,2′,5,6′-tetrahydroxybenzophenone, guttiferone E, isogarcinol and isoxanthochymol. Phytomedicine 20:528–536PubMedCrossRef
13.
Kuete V, Sandjo L, Nantchouang Ouete J, Fouotsa H, Wiench B, Efferth T (2013) Cytotoxicity and modes of action of three naturally occuring xanthones (8-hydroxycudraxanthone G, morusignin I and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines. Phytomedicine 21:315–322PubMedCrossRef
14.
Kuete V, Sandjo L, Wiench B, Efferth T (2013) Cytotoxicity and modes of action of four Cameroonian dietary spices ethno-medically used to treat Cancers: Echinops giganteus, Xylopia aethiopica, Imperata cylindrica and Piper capense. J Ethnopharmacol 149:245–253PubMedCrossRef
15.
O’Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421–5426PubMedCrossRef
16.
Kuete V, Fankam AG, Wiench B, Efferth T (2013) Cytotoxicity and Modes of Action of the Methanol Extracts of Six Cameroonian Medicinal Plants against Multidrug-Resistant Tumor Cells. Evid Based Complement Alternat Med 2013:285903PubMedCentralPubMed
17.
Kuete V, Tankeo SB, Saeed ME, Wiench B, Tane P, Efferth T (2014) Cytotoxicity and modes of action of five Cameroonian medicinal plants against multi-factorial drug resistance of tumor cells. J Ethnopharmacol 153:207–219PubMedCrossRef
18.
Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 130:1910–1917PubMed
19.
Cossarizza A, Ferraresi R, Troiano L, Roat E, Gibellini L, Bertoncelli L, Nasi M, Pinti M (2009) Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc 4:1790–1797PubMedCrossRef
20.
Endale M, Ekberg A, Alao JP, Akala HM, Ndakala A, Sunnerhagen P, Erdelyi M, Yenesew A (2012) Anthraquinones of the roots of Pentas micrantha. Molecules 18:311–321PubMedCrossRef
21.
Guido R, Menavanza N, Kurt H (1995) Anthraquinones from Morinda lucida. Int J Pharmacogn 33:107–114CrossRef
22.
Donfack A, Tala M, Wabo H, Jerz G, Zeng G-Z, Winterhalter P, Tan N-H, Tane P (2014) Two new anthraquinone dimers from the stem bark of Pentas schimperi (Rubiaceae). Phytochemistry Lett 8:55–58CrossRef
23.
Kuete V, Sandjo LP, Djeussi DE, Zeino M, Kwamou GM, Ngadjui B, Efferth T (2014) Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells. Invest New Drugs 32:1053–1062PubMedCrossRef
24.
Boik J (2001) Natural compounds in cancer therapy. Oregon Medical Press, Minnesota USA
25.
Brahemi G, Kona FR, Fiasella A, Buac D, Soukupova J, Brancale A, Burger AM, Westwell AD (2010) Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer. J Med Chem 53:2757–2765PubMedCentralPubMedCrossRef
26.
27.
Thani W, Vallisuta O, Siripong P, Ruangwises N (2010) Anti-proliferative and antioxidative activities of Thai noni/Yor (Morinda citrifolia Linn.) leaf extract. Southeast Asian J Trop Med Public Health 41:482–489PubMed
28.
Abu N, Ali NM, Ho WY, Yeap SK, Aziz MY, Alitheen NB (2014) Damnacanthal: a promising compound as a medicinal anthraquinone. Anticancer Agents Med Chem 14:750–755PubMedCrossRef
29.
Aziz MY, Omar AR, Subramani T, Yeap SK, Ho WY, Ismail NH, Ahmad S, Alitheen NB (2014) Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells. Oncol Lett 7(5):1479–1484PubMedCentralPubMed
30.
Dibwe DF, Awale S, Kadota S, Tezuka Y (2012) Damnacanthal from the Congolese medicinal plant Garcinia huillensis has a potent preferential cytotoxicity against human pancreatic cancer PANC-1 cells. Phytother Res 26:1920–1926PubMedCrossRef
31.
Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J (1996) Human ICE/CED-3 protease nomenclature. Cell 87:171PubMedCrossRef
32.
Patterson LH (1993) Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 12:119–134PubMedCrossRef
33.
Wu W, Yan R, Yao M, Zhan Y, Wang Y (1996) Pharmacokinetics of anthraquinones in rat plasma after oral administration of a rhubarb extract. Biomed Chromatogr 28:564–572CrossRef
34.
Ma YS, Weng SW, Lin MW, Lu CC, Chiang JH, Yang JS, Lai KC, Lin JP, Tang NY, Lin JG, Chung JG (2012) Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model. Food Chem Toxicol 2012(50):1271–1278CrossRef
Metadata
Title
Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells
Authors
Victor Kuete
Arno R. Nanfack Donfack
Armelle T. Mbaveng
Maen Zeino
Pierre Tane
Thomas Efferth
Publication date
01-08-2015
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-015-0268-9

Other articles of this Issue 4/2015

Investigational New Drugs 4/2015 Go to the issue

PRECLINICAL STUDIES

Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties

PHASE I STUDIES

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)

PRECLINICAL STUDIES

In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis

PRECLINICAL STUDIES

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs

PHASE II STUDIES

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

PHASE II STUDIES

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits